Introduction {#s1}
============

Chronic progressive external ophthalmoplegia (CPEO) is a slowly progressive extraocular muscle disorder characterised by bilateral, usually symmetrical, limitation of eye movements and ptosis [@pone.0075048-Richardson1]. This classical manifestation of mitochondrial diseases can develop either in isolation or in association with other disabling neurological features, referred to as CPEO+ [@pone.0075048-McFarland1], [@pone.0075048-Fraser1]. Unsurprisingly, CPEO results in significant morbidity with a marked negative impact on the patient's quality of life [@pone.0075048-YuWaiMan1]. Molecularly, CPEO can be classified into two distinct genetic subgroups depending on whether patients harbour single, large-scale mitochondrial DNA (mtDNA) deletions or multiple mtDNA deletions secondary to a nuclear mutation disrupting mtDNA replication or repair [@pone.0075048-Greaves1], [@pone.0075048-YuWaiMan2].

The aim of this magnetic resonance imaging (MRI) study was to investigate whether the limitation of eye movements in CPEO is myopathic in origin or whether there is evidence of contributory brainstem dysfunction with magnetic resonance spectroscopy (MRS). Brain volumetric measurements were also performed to assess the extent of central nervous system involvement and whether this correlated with the development of extraocular neurological features in patients with CPEO+ phenotypes.

Patients and Methods {#s2}
====================

Study Cohort {#s2a}
------------

The study cohort included: (i) nine patients with single, large-scale mtDNA deletions (six females and three males, mean age = 50.8 years, standard deviation (SD) = 3.0 years), (ii) eleven patients with multiple mtDNA deletions (four females, seven males, mean age = 51.6 years, SD = 2.8 years), and (iii) ten age-matched normal controls (seven females and three males, mean age 50.3, SD = 2.3 years) ([**Table 1**](#pone-0075048-t001){ref-type="table"}). Recruitment was limited to patients younger than 70 years of age to exclude possible age-related confounding factors, and to those with disease duration of more than five years. This study had the relevant institutional ethical approval (County Durham & Tees Valley 1 Research Ethics Committee, 08/H0905/106) and it was carried out in compliance with the Declaration of Helsinki. Participants provided their written consent for participation into this study.

10.1371/journal.pone.0075048.t001

###### Clinical and molecular genetic characteristics of the CPEO cohort.

![](pone.0075048.t001){#pone-0075048-t001-1}

  Patient                          Genetic defect                          Age   Sex   EOM limitation   Ptosis severity   Diplopia               Additional neurological complications
  --------- ------------------------------------------------------------- ----- ----- ---------------- ----------------- ---------- ---------------------------------------------------------------
  1                        Single mtDNA deletion (2.9 Kb)                  66     M          −3            Moderate         Yes               Myopathy, cerebellar dysfunction, migraine
  2                        Single mtDNA deletion (5.0 Kb)                  45     F          −3             Severe          Yes                Myopathy, cerebellar dysfunction, fatigue
  3                        Single mtDNA deletion (7.7 Kb)                  61     F          −4            Moderate         Yes                                Myopathy
  4                        Single mtDNA deletion (5.0 Kb)                  57     F          −3            Moderate         Yes                                Myopathy
  5                        Single mtDNA deletion (6.5 Kb)                  42     F          −3               Nil           Yes                                 Fatigue
  6                        Single mtDNA deletion (5.0 Kb)                  54     M          −3             Severe           No                                   --
  7                        Single mtDNA deletion (4.8 Kb)                  46     M          −4             Severe           No                                   --
  8                        Single mtDNA deletion (4.6 Kb)                  41     F          −3            Moderate         Yes                                   --
  9                        Single mtDNA deletion (5.0 Kb)                  45     M          −3             Severe          Yes                           Myopathy, epilepsy
  10           Multiple mtDNA deletions (*POLG*; p.A467T/p.Arg1096Cys)     42     M          −3             Severe           No         Myopathy, cerebellar dysfunction, peripheral neuropathy
  11         Multiple mtDNA deletions (*POLG*; p.Trp748Ser/p.Arg1096Cys)   54     M          −2              Mild           Yes      Ataxia, epilepsy, peripheral neuropathy, cognitive impairment
  12          Multiple mtDNA deletions (*POLG*; p.Ala467Thr/p.X1240Gln)    52     F          −3            Moderate          No                 Ataxia, epilepsy, peripheral neuropathy
  13         Multiple mtDNA deletions (*POLG*; p.Ala467Thr/p.Ala467Thr)    43     M          −3              Mild           Yes          Peripheral neuropathy, myalgia, cognitive impairment
  14               Multiple mtDNA deletions (*PEO1*; p.Arg374Gln)          36     M          −3            Moderate          No                            Myopathy, fatigue
  15               Multiple mtDNA deletions (*PEO1*; p.Arg334Gln)          61     M          −3            Moderate          No                                   --
  16               Multiple mtDNA deletions (*PEO1*; p.Leu381Pro)          58     F          −3             Severe           No                                 Myalgia
  17               Multiple mtDNA deletions (*OPA1*; p.Ile432Val)          42     M          −2            Moderate          No      Myopathy, peripheral neuropathy, ataxia, cognitive impairment
  18               Multiple mtDNA deletions (*RRM2B*; p.Ile224Ser)         61     F          −4            Moderate         Yes                                Myopathy
  19             Multiple mtDNA deletions (Unknown nuclear mutation)       60     M          −2             Severe           No                          Myopathy, dysarthria
  20             Multiple mtDNA deletions (Unknown nuclear mutation)       59     F          −3             Severe           No                         Cerebellar dysfunction

EOM = extraocular muscle; F = female; M = male.

Clinical and Molecular Investigations {#s2b}
-------------------------------------

All patients were assessed by an experienced multi-disciplinary team of neurologists and ophthalmologists to define the clinical phenotype and disease severity ([**Table 1**](#pone-0075048-t001){ref-type="table"}). The limitation of eye movements was quantified from −1 to −4, with −1 indicating only mild limitation and −4 being the worst score, the eye being unable to move from the primary position of gaze [@pone.0075048-Vivian1]. Ptosis severity was graded according to the height of the palpebral aperture: (i) severe (\<4 mm), (ii) moderate (4--6 mm), and (iii) mild (\>6 mm) [@pone.0075048-Taherian1]. Additional histochemical and molecular investigations were carried out on skeletal muscle biopsies to confirm the clinical diagnosis of CPEO. A nuclear mutation was identified in nine of the eleven patients with CPEO found to harbour multiple mtDNA deletions: (i) *POLG* mutations (n = 4) [@pone.0075048-Horvath1], *PEO1* mutations (n = 3) [@pone.0075048-Fratter1], *OPA1* mutations (n = 1) [@pone.0075048-YuWaiMan3], and *RRM2B* mutations (n = 1) [@pone.0075048-Fratter2]. For two patients, an underlying nuclear genetic defect has so far not been identified. Both these patients had typical clinical features of CPEO and mitochondrial histochemistry performed on skeletal muscle biopsies showed high levels of cytochrome *c* oxidase-deficient fibres in addition to prominent ragged red fibres.

Magnetic Resonance Studies {#s2c}
--------------------------

MRI and MRS data were acquired on a 3-Tesla Philips Achieva clinical MR system using an 8-channel head coil. Proton MRS analysis was performed by an experienced research physicist (FES) to derive brain metabolite concentrations in the parietal white matter and brainstem regions: (i) choline; (ii) creatine; (iii) total glutamate and glutamine (Glx); (iv) myo-inositol; and (v) N-acetyl-aspartate (NAA). Extraocular and brain compartment volumes were measured using standardised semi-automated segmentation protocols (**[Text S1](#pone.0075048.s005){ref-type="supplementary-material"}**), with a high degree of intra- and inter-observer reliability (**[Table S1](#pone.0075048.s004){ref-type="supplementary-material"}**).

Statistical Analysis {#s2d}
--------------------

Statistical analysis was performed using GraphPad™ Prism v5 statistical software (San Diego, CA). Group comparisons were made using the unpaired t-test. Intra-observer and inter-observer variability for the measurement of extraocular muscle and brain volumes was assessed with Pearson correlation coefficient (r).

Results {#s3}
=======

Extraocular Muscle Morphology {#s3a}
-----------------------------

There was a significant reduction in extraocular muscle volumes in the CPEO group compared with normal controls for all four recti muscles ([**Figure 1**](#pone-0075048-g001){ref-type="fig"}), ranging from 24.7% to 40.2% ([**Table 2**](#pone-0075048-t002){ref-type="table"} **and** [**Figure 2**](#pone-0075048-g002){ref-type="fig"}). No significant difference in extraocular muscle volumes was found between the two eyes from the same patient ([**Table 3**](#pone-0075048-t003){ref-type="table"} **and** [**Figure 3**](#pone-0075048-g003){ref-type="fig"}). No specific MRI signal abnormalities were identified along the course of the extraocular muscles in patients with CPEO harbouring either single or multiple mtDNA deletions.

![Extraocular muscle morphology in patients with CPEO and controls.\
Representative cross-sections of extraocular muscles have been provided at three different anatomical locations. All four recti muscles in patients harbouring single, large-scale deletions or multiple DNA deletions were atrophic compared with controls. Slice locations: I = 4 mm behind slice II towards the orbital apex; II = central slice; III = 4 mm in front of slice II towards the extraocular muscle insertions onto the globe.](pone.0075048.g001){#pone-0075048-g001}

![Comparison of extraocular muscle volumes between patients with CPEO and controls.\
Box plot of extraocular muscle volume data with the whiskers representing the minimum and maximum volumes. The ends of the boxes are the upper and lower quartiles, the vertical lengths of the boxes indicate the interquartile range, and the lines within the boxes represent the median volume for each group. CPEO cohort: single = single mtDNA deletion; multiple = multiple mtDNA deletions.](pone.0075048.g002){#pone-0075048-g002}

![Interocular correlation of extraocular muscle volumes in patients with CPEO.\
r = Pearson correlation coefficient.](pone.0075048.g003){#pone-0075048-g003}

10.1371/journal.pone.0075048.t002

###### Extraocular muscle volumes in patients with CPEO and controls.
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  Genetic group                                 Superior rectus      Inferior rectus       Medial rectus        Lateral rectus
  ------------------------------------------- -------------------- -------------------- -------------------- --------------------
  **Single mtDNA deletion** **(n = 9)**        582.6±41.8 (35.4%)   525.0±30.6 (28.2%)   556.6±17.9 (32.3%)   629.3±25.9 (24.7%)
                                                   P\<0.0001            P\<0.0001            P\<0.0001            P\<0.0001
  **Multiple mtDNA deletions** **(n = 11)**    547.3±23.7 (39.4%)   523.1±19.9 (28.5%)   491.8±20.3 (40.2%)   589.1±23.6 (29.5%)
                                                   P\<0.0001            P\<0.0001            P\<0.0001            P\<0.0001
  **Controls (n = 10)**                            902.4±35.9           731.5±26.9           822.6±30.1           835.3±34.5

Percentage reduction compared with controls. The respective P values indicate the level of significance for the comparisons with the control data set. SD: standard deviation.

10.1371/journal.pone.0075048.t003

###### Interocular comparison of extraocular muscle volumes in patients with CPEO.
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  Anatomical side           Superior rectus   Inferior rectus   Medial rectus   Lateral rectus
  ------------------------ ----------------- ----------------- --------------- ----------------
  **Left eye (n = 20)**       556.4±27.0        502.5±26.8       514.0±17.2       593.6±24.6
  **Right eye (n = 20)**      569.9±37.3        545.4±21.6       527.9±23.9       620.7±25.2
  **P value**                   0.7707            0.2205           0.6374           0.4469

The P value for each rectus muscle indicates the level of significance for the comparison between the left and right eye. SD = standard deviation.

Brain Metabolites and Compartment Volumes {#s3b}
-----------------------------------------

There was no significant difference in metabolite concentrations between the patient and control groups in both the parietal white matter and brainstem voxels ([**Table 4**](#pone-0075048-t004){ref-type="table"}). There was a statistically significant reduction in total grey matter and cerebellar volumes for both patients with single deletions and multiple mtDNA deletions ([**Table 5**](#pone-0075048-t005){ref-type="table"}). On subgroup analysis, the reduction in total grey matter and cerebellar volumes was apparent for patients with CPEO+, but not for those with pure CPEO phenotypes ([**Figure 4**](#pone-0075048-g004){ref-type="fig"}).

![Comparison of brain compartment volumes between patients with CPEO and controls.](pone.0075048.g004){#pone-0075048-g004}

10.1371/journal.pone.0075048.t004

###### Metabolite concentrations in parietal white matter and brainstem regions.

![](pone.0075048.t004){#pone-0075048-t004-4}

  Voxel location                           Subject group                Choline      Creatine       Glx       Myo-inositol      NAA
  --------------------------- --------------------------------------- ------------ ------------ ------------ -------------- ------------
  **Parietal white matter**      **Single mtDNA deletion (n = 9)**      1.5±0.1      10.0±1.4     28.9±1.8      2.8±0.7       15.4±1.0
                                                                       P = 0.1970   P = 0.1428   P = 0.2636    P = 0.4628    P = 0.5933
                               **Multiple mtDNA deletions (n = 11)**    1.4±0.1      10.4±0.5     25.6±1.6      1.8±0.3       13.0±0.9
                                                                       P = 0.7495   P = 0.0825   P = 0.0451    P = 0.1703    P = 0.0171
                                       **Controls (n = 10)**            1.3±0.3      12.5±2.7     32.8±2.9      4.4±2.1       16.0±0.7
  **Brainstem**                  **Single mtDNA deletion (n = 9)**      1.5±0.1      10.7±0.6     28.0±2.0      4.1±0.6       11.1±0.5
                                                                       P = 0.4266   P = 0.7425   P = 0.6837    P = 0.2336    P = 0.3711
                               **Multiple mtDNA deletions (n = 11)**    1.4±0.1      10.0±1.2     23.5±3.1      4.2±0.9       11.8±0.9
                                                                       P = 0.3260   P = 0.5836   P = 0.4064    P = 0.2865    P = 0.8390
                                       **Controls (n = 10)**            1.7±0.6      11.0±2.5     26.7±2.2      5.9±1.3       12.1±0.8

The respective P values indicate the level of significance for the comparisons with the control data set, with P\<0.0167 being the threshold level for statistical significance after Bonferroni correction for multiple testing.

10.1371/journal.pone.0075048.t005

###### Volumetric brain measurements in patients with CPEO harbouring single and multiple mtDNA deletions.
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  Genetic group                                   Grey matter         White matter         Brainstem         Cerebellum
  ------------------------------------------- -------------------- ------------------- ----------------- -------------------
  **Single mtDNA deletion** **(n = 9)**         594.2±9.6 (6.6%)    437.9±14.2 (7.9%)   28.2±0.8 (7.2%)   112.6±3.9 (10.8%)
                                                   P = 0.0402          P = 0.1168         P = 0.0575         P = 0.0094
  **Multiple mtDNA deletions** **(n = 11)**    572.3±22.7 (10.1%)   462.8±20.7 (2.6%)   28.1±1.1 (7.6%)   111.0±4.0 (12.1%)
                                                   P = 0.0344          P = 0.6516         P = 0.1012         P = 0.0061
  **Controls (n = 10)**                            636.5±15.8          475.3±17.3          30.4±0.6           126.3±2.7

Percentage reduction compared with controls. The respective P values indicate the level of significance for the comparisons with the control data set. SD = standard deviation.

Discussion {#s4}
==========

This study has shown clear evidence of significant extraocular muscle atrophy involving all four recti muscles in CPEO. This striking observation was noted for both patients with single, large-scale mtDNA deletions and for those harbouring multiple mtDNA deletions secondary to an underlying nuclear genetic defect. In a previous report of nine patients with CPEO, *Carlow and colleagues* observed a significant reduction in extraocular muscle volumes for the inferior rectus, medial rectus and lateral rectus [@pone.0075048-Carlow1]. The superior rectus was not assessed in their study and the diagnosis of CPEO was made on clinical grounds, precluding any genetic subgroup analysis. In a subsequent study, *Ortube and colleagues* measured extraocular muscle volumes in five patients with a clinical diagnosis of CPEO [@pone.0075048-Ortube1]. In contrast to the findings of our study, a reduction in extraocular muscle volume was noted for the superior rectus muscle only, but not for the other recti muscles despite a severe degree of ophthalmoplegia. There were, however, a number of limitations to the study by *Ortube and colleagues*, including the relatively small number of patients that were recruited and the lack of a confirmatory molecular diagnosis. Furthermore, only a relatively small portion of the extraocular muscle belly was sampled, which could have underestimated the degree of atrophy in the recti muscles.

Our study is the first to demonstrate objectively that the extent of extraocular muscle atrophy in CPEO is highly symmetrical between the two eyes of the same patient, reflecting the ophthalmoplegia pattern observed clinically [@pone.0075048-Richardson1]. No specific MRI signal abnormalities were identified throughout the whole length of the extraocular muscles in the twenty patients with CPEO that were investigated. A number of other ocular motility disorders can result in bilateral progressive ophthalmoplegia and differentiating these from CPEO can sometimes be challenging, especially when access to specialist mitochondrial genetic services is not routinely available. Although future prospective studies are needed to clarify this further, based on their characteristic extraocular muscle differences, MRI evaluation of the orbit could prove a useful adjunct in the diagnostic evaluation of this group of patients.

A variable decrease in N-acetyl-aspartate (NAA) has previously been reported in the brain of patients with the Kearns-Sayre syndrome -- a particularly severe clinical phenotype characterised by the development of CPEO and pigmentary retinopathy before the age of twenty years, often in association with progressive cardiac conduction block [@pone.0075048-Matthews1], [@pone.0075048-Kapellar1]. There was no significant difference in metabolite concentrations between the CPEO and control groups in our study. These proton MRS findings are consistent with the later onset and less severe neurological course in the patients that were recruited, none of whom fulfilled the criteria for the Kearns-Sayre syndrome.

Patients with CPEO+ features had significantly reduced total grey matter and cerebellar volumes compared with controls, in keeping with the higher burden of neurological disease in this specific patient population. The prominent degree of atrophy seen in the cerebellum further highlights the particular vulnerability of this specific brain region to the deleterious consequences of mtDNA defects [@pone.0075048-Wray1], [@pone.0075048-Lax1]. Patients with CPEO did not have significantly reduced brainstem volumes compared with controls and no brainstem metabolite abnormalities were detected with proton MRS. These observations, taken in conjunction with the marked atrophy of the extraocular muscles, support a primary myopathic origin for the progressive ophthalmoplegia seen in CPEO. However, some caution is required with regards to the subgroup comparisons given the relatively small number of patients in the single and multiple mtDNA deletion groups, and the different nuclear genetic defects involved. Furthermore, although CPEO is characterised by a significant myopathy involving the extraocular muscles, the degree of atrophy observed could still result, at least partly, from degeneration of the oculomotor nuclei as has been observed in some patients [@pone.0075048-Daroff1], [@pone.0075048-Palin1].

This comprehensive magnetic resonance study of patients with molecularly confirmed CPEO has revealed a number of important findings that are directly relevant to our understanding of the underlying pathophysiology in this mitochondrial ocular disorder. In addition to marked generalised extraocular muscle atrophy, there was clear evidence of significant CNS involvement in this disorder, which becomes clinically manifest in a subgroup of patients.
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